Research summary, original research, 2015

Patient And Staff Doses In Paediatric Interventional Cardiology Derived From Experimental Measurements With Phantoms

Ubeda C, Vano E, Miranda P, Aguirre D, Riquelme N, Dalmazzo D, et al.. Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB). 2015

Read the original paper

In plain language

In phantom-based estimates for paediatric interventional cardiology in Chile, scatter dose to the cardiologist's eyes ranged from 0.20 to 116 µSv per procedure, and doses differed widely between X-ray systems. These are estimates, not health outcomes.

At a glance

Type of study
Original research, Phantom or simulation study
Who was studied
Interventional cardiologists, Patients, Phantom or simulation (no people)
Where
Chile
Summary based on
the abstract

What it found

  • Simulated scatter doses at the cardiologist's eyes varied widely across paediatric procedures.

    Key figures: 0.20 to 116 µSv per procedure

  • Cumulative patient entrance surface air kerma varied widely across simulated procedures.

    Key figures: 2 to 1100 mGy

  • Kerma-area product values ranged widely.

    Key figures: 0.30 to 150 Gy cm(2)

  • Large differences between X-ray systems were found, and the authors call for standardized system settings and protocols in Chile.

Limits to keep in mind

Doses were derived from PMMA phantom measurements combined with average fluoroscopy time and cine frame counts rather than measured on staff during real procedures. The abstract does not state the number of X-ray systems or hospitals.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.